Global R&D Partner Aris Pharmaceuticals serves 300 pharmaceutical, biotechnology and agrochemical companies worldwide, offering chemistry services and intermediate API supply, presenting a broad potential for multi-region collaboration and supplier diversification.

In-House Innovation Four in-house anti-viral R&D programs including first-in-class HIV inactivators signal a strong emphasis on novel therapeutic platforms, presenting opportunities for collaboration on early-stage discovery chemistry, scale-up, and tailored synthesis for viral targets.

Scalable Capabilities Laboratory and kilo-scale synthesis capabilities with semi-bulk and bulk intermediates, plus a 12,000 ft2 Shanghai facility, enable scalable production for rapid pilot runs and supply chain redundancy across regions.

Extensive Catalog An 8500-scaffold catalog with 60% in stock and 90% potentially available within 1–2 weeks supports fast turnaround for library synthesis, custom intermediates, and back-up sourcing for project timelines.

Strategic Fit Small to mid-size company profile with global reach and a focus on dependable, cost-efficient delivery aligns well with CRO/drug discovery partnerships seeking agile chemistry services and reliable API sourcing.